TM · NYSE
| FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $29.93T | $30.23T | $29.38T | $27.60T | — | — | — | $234.60B |
| Cost of Revenue | — | — | — | — | — | — | — | $191.50B |
| Research & Development | — | — | — | — | — | — | — | $8.59B |
| Selling, General & Administrative | — | — | — | — | — | — | — | $22.35B |
| Operating Expenses | — | — | — | — | — | — | — | $220.56B |
| Operating Income | — | — | — | — | — | — | — | $14.04B |
| Interest Expense | $512.68B | $499.87B | $415.09B | $352.69B | $377.31B | $347.03B | $316.05B | $244.00M |
| Other Income / (Expense) | — | — | — | — | — | — | — | $880.00M |
| Income Before Taxes | — | — | — | — | — | — | — | $14.93B |
| Provision for Income Taxes | — | — | — | — | — | — | — | $5.87B |
| Net Income | — | — | — | — | — | — | — | $10.23B |
| Basic EPS | — | — | — | — | — | — | — | $3.23 |
| Diluted EPS | — | — | — | — | — | — | — | $3.23 |
| Basic Shares Outstanding | 2.80B | 2.87B | 2.95B | 3.01B | 3.11B | 3.16B | 3.17B | 3.17B |
| Diluted Shares Outstanding | 2.85B | 2.92B | 2.99B | 3.06B | 3.14B | 3.16B | 3.17B | 3.17B |
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Mar 2027 | $20.05 | $18.31 | $23.29 | 3 | ↑0 ↓1 |
| Mar 2028 | $23.19 | $20.57 | $27.94 | 3 | ↑0 ↓1 |
| Mar 2029 | $32.29 | $32.29 | $32.29 | 1 | ↑0 ↓0 |